Big Idea Voting


Check out the latest edition of HOPA News!


Latest Discussions

HOPA Bulletin

  • An immunotherapy approach that uses a new method of preparing immune cells may provide a potential treatment option for some patients with acute myeloid leukemia (AML), results from an early-stage clinical trial suggest.

    In the phase I trial, researchers collected the immune cells, called natural killer (NK) cells, from donors, manipulated them to be better cancer killers, and infused the cells into patients with AML who had previously exhausted all other treatment options. The approach — which uses a new method of manipulating NK cells that is different from those used in prior studies — led to partial or complete remissions in five out of the nine patients who could be evaluated. It also appeared to be safe, with patients experiencing only minor side effects.

Getting Started

Check out our user guide for further information.

Connect With Us